Neuromyelitis optica News and Research

RSS

Study reveals safety of MS drugs during breastfeeding in child's early years of life

Certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child during the first three years of life, according to a preliminary study released today, March 4, 2024.

4 Mar 2024

New mechanism discovered: B cells' contribution to immune tolerance in thymus gland

Immune cells must learn not to attack the body itself. A team of researchers from the Technical University of Munich (TUM) and the Ludwig Maximilian University of Munich (LMU) has discovered a previously unknown mechanism behind this: other immune cells, the B cells, contribute to the "training" of the T cells in the thymus gland.

21 Feb 2024

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

Researchers performed an observational study among COVID-19 patients and their close contacts registered with the Bangkok home health care services in Thailand.

18 Jan 2023

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

A new review discussed the applications of single-cell ribonucleic acid sequencing (scRNA-seq) in understanding autoimmune disorders.

17 Oct 2022

IRIS Registry presents latest eye research at AAO 2022

The IRIS Registry (Intelligent Research in Sight) powered several big data studies this year, most of which will be presented and discussed at AAO 2022 Gather, the 126th annual meeting of the American Academy of Ophthalmology.

30 Sep 2022

Hybrid immunity retained six months after SARS-CoV-2 exposure

Scientists hypothesize that lower death rates in COVID-19 patients may be due to hybrid immunity, as well as the reduced severity of Omicron infections.

3 Aug 2022

The effects and mechanisms of SARS-CoV-2 on the nervous system

Researchers reviewed the neurologic manifestations associated with SARS-CoV-2.

30 Jun 2022

Antibody treatment improves symptoms of neuromyelitis optica in a rat model

Autoimmune diseases are the molecular equivalent of "friendly fire": the body attacks itself instead of harmful invaders.

11 Mar 2022

Blacks, Latinos with autoimmune diseases experience poorer outcomes due to modifiable social conditions

Minority populations in the US with multiple sclerosis and other autoimmune diseases experience poorer outcomes due to modifiable social conditions, according to a new USC study.

5 Oct 2021

New research may offer clues to why MS patients develop progressive disability

Did you know multiple sclerosis (MS) means multiple scars? New research shows that the brain and spinal cord scars in people with MS may offer clues to why they developprogressive disability but those with related diseases where the immune system attacks the central nervous system do not.

19 Jul 2021

Dying patients with rare diseases struggle to get experimental therapies

At 15, Autumn Fuernisen is dying. She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington's disease.

14 Jul 2021

Researchers develop a classification scheme for neuromyelitis optica spectrum disorder

Researchers in the Department of Neurology at Tohoku University, which is led by professor Masashi Aoki, have developed a classification scheme for neuromyelitis optica spectrum disorder, a rare autoimmune disease that until recently was thought to be a type of multiple sclerosis (MS).

15 Apr 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

How do low levels of oxygen damage the brain?

In this interview, Professor Paul Tesar and Kevin Allan speak to News-Medical about how low levels of oxygen damage the brain.

6 Nov 2020

Home-based pediatric teleneuropsychology evaluations shown to be effective

Administering neuropsychology evaluations to children online in the comfort of their own homes is feasible and delivers results comparable to tests traditionally performed in a clinic, a new study led by UT Southwestern researchers and Children's Health indicates.

24 Sep 2020

FDA approves drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody - patients who are anti-aquaporin-4 or AQP4 antibody-positive.

17 Aug 2020

Study: Certain inflammatory demyelinating diseases belong to different category than multiple sclerosis

An antibody appears to make a big difference between multiple sclerosis and other disorders affecting the protective myelin sheath around nerve fibers, report Tohoku University scientists and colleagues in the journal Brain.

19 May 2020

New nanobiosensor can help diagnose early-stage multiple sclerosis

Researchers at the Federal University of São Carlos in Sorocaba have developed a technique to diagnose early-stage multiple sclerosis, a disease of the central nervous system, and distinguish it from neuromyelitis optica, a rare yet severe autoimmune inflammatory process also affecting the central nervous system.

23 Apr 2020

Cytel hosts Complex Innovative Trial Design Symposium and East Training in Boston

Cytel Inc., the leading global provider of innovative analytical software and consulting services to the life sciences industry, has announced that the Complex Innovative Trial Design Symposium and East Training will take place November 6–7 at Alexion’s headquarters in Boston, Massachusetts.

From Cytel 18 Oct 2019

FDA approves first drug for treatment of neuromyelitis optica spectrum disorder

The U.S. Food and Drug Administration today approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive.

27 Jun 2019